SecBot SecBot
8-K ·Filed May 4, 2026

TWST

Twist Bioscience Corp
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001581280-26-000037
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The revenue beat and guidance raise confirm accelerating momentum across both DSPS and NGS segments, with the company on track for Q4 adjusted EBITDA breakeven. The litigation settlement is a one-time charge that does not affect the underlying operational trajectory. Watch for continued NGS acceleration in H2 and any updates on the AWS partnership and Invenra licensing deal.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$56.19
T+0 close · May 4, 2026 · via day close
Latest settled
+52.11%
T+60 · $85.47
Vs SPY
+50.25%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 4 $56.19entry
  2. T+1 · 7mo ago +0.91%α +0.11% · $56.70
  3. T+5 · 6mo ago +0.04%α −2.90% · $56.21
  4. T+20 · 6mo ago +20.77%α +15.12% · $67.86
  5. T+60 · 4mo ago +52.11%α +50.25% · $85.47
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Twist Bioscience reported fiscal Q2 2026 revenue of $110.7M, a 19% YoY increase and above the prior quarter's $103.7M, while raising full-year FY2026 revenue guidance to $442M-$447M from $435M-$440M. GAAP net loss widened to $0.71/share from $0.66/share a year ago due to a $7.2M litigation settlement charge, but adjusted EBITDA improved to -$13.3M from -$14.8M. The company reiterated its Q4 FY2026 adjusted EBITDA breakeven target, and both DSPS (+28%) and NGS (+12%) segments showed strong growth.

Key Financial Metrics

EPS
−$0.71
Revenue
$110.7M
+19.3% YoY
Rating
beat
Guidance
$442M-$447M
raised
Gross Margin
51.6%

Key Facts

  • Q2 FY2026 revenue of $110.7M, up 19% YoY from $92.8M, exceeding the prior quarter's $103.7M and the company's own guidance
  • Full-year FY2026 revenue guidance raised to $442M-$447M from $435M-$440M, implying 17%-19% YoY growth
  • Q3 FY2026 revenue guided to ~$114M-$115M, ~19% YoY growth at the midpoint
  • GAAP net loss per share was -$0.71 vs -$0.66 a year ago, including a $7.2M litigation settlement charge
  • Adjusted EBITDA improved to -$13.3M from -$14.8M in the year-ago quarter
  • DSPS revenue grew 28% YoY to $53.3M; NGS revenue grew 12% YoY to $57.4M
  • Gross margin improved to 51.6% from 49.6% a year ago
  • Cash and short-term investments stood at ~$172M as of March 31, 2026
  • Company reiterated achieving adjusted EBITDA breakeven in Q4 FY2026
  • Entered into a bispecific licensing agreement with Invenra and was named an AWS wet lab partner for Amazon Bio Discovery

Financial Impact

Revenue beat internal guidance by ~$2-3M; full-year guidance raised by $7M at the midpoint; net loss widened by $4.7M due to a $7.2M litigation charge

revenuenet lossadjusted EBITDAgross margin

Risk Factors

  • GAAP net loss widened to -$0.71/share, and the company remains unprofitable on a GAAP basis
  • Cash burn continues, cash and short-term investments declined from $198M to $172M over the quarter
  • Litigation settlement of ~$17.1M (with $7.2M booked this quarter) is a cash outflow risk
  • Dependence on a single supplier for a critical component and potential supply chain disruptions
  • Forward-looking statements on profitability and growth are subject to market conditions and execution risk

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
82% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001581280-26-000037
Document: twist-20260504.htm0001581280-26-000037
Document: 0001581280-26-000037-index-headers.html0001581280-26-000037
Document: 0001581280-26-000037-index.html0001581280-26-000037
Document: 0001581280-26-000037.txt0001581280-26-000037
8-K Data (Synthetic)0001581280-26-000037

US Market Status

Market Closed · Opens Wed (13h 53m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 4, 2026